Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

Journal of the Neurological Sciences

Volumn 252, Issue 1, 2007, Pages 57-61

  Warabi, Yoko ^a,b   Matsumoto, Yoh ^b   Hayashi, Hideaki ^a  

^a TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Blindness; CSF pleocytosis; Interferon beta 1b; Longitudinally extensive spinal cord lesion (LESL); Multiple sclerosis; Neuromyelitis optica

Indexed keywords

INTERFERON BETA SERINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASIAN; BLINDNESS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENETIC TRAIT; HETEROZYGOTE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OPTIC NERVE LESION; PLEOCYTOSIS; PRIORITY JOURNAL; SKIN ULCER; SPINAL CORD LESION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ALLELES; DISABILITY EVALUATION; FEMALE; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; OPTIC NERVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINAL CORD; SPINAL CORD DISEASES;

EID: 33845439133     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.10.008     Document Type: Article

References (12)

1. Saida T., Tashiro K., Itoyama Y., Sato T., Ohashi Y., and Zhao Z. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64 4 (2005) 621-630
2. Fukazawa T., Kikuchi S., Niino M., Yabe I., Miyagishi R., Fukaura H., et al. Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders. J Neurol Sci 225 1-2 (2004) 71-78
3. Fukazawa T., Kikuchi S., Miyagishi R., Miyazaki Y., Fukaura H., Yabe I., et al. CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria. J Neurol 252 7 (2005) 824-829
4. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., and Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 5 (1999) 1107-1114
5. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50 1 (2001) 121-127
6. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., and Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch Neurol 63 3 (2006) 390-396
7. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., and Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66 10 (2006) 1485-1489
8. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 9451 (2004) 2106-2112
9. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., and Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 4 (2005) 473-477
10. Nakashima I., Fujihara K., Miyazawa I., Misu T., Narikawa K., Nakamura M., et al. Clinical and MRI features of Japanese MS patients with NMO-IgG. J Neurol Neurosurg Psychiatry 77 9 (2006) 1073-1075
11. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 4 (1996) 907-911
12. *0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 122 Pt 9 (1999) 1689-1696